605 related articles for article (PubMed ID: 30242397)
21. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs.
Falchook AD; Salloum RG; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):243-8. PubMed ID: 24321784
[TBL] [Abstract][Full Text] [Related]
22. Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
Jacobs BL; Lopa SH; Yabes JG; Nelson JB; Barnato AE; Degenholtz HB
Cancer; 2016 Oct; 122(20):3199-3206. PubMed ID: 27379732
[TBL] [Abstract][Full Text] [Related]
23. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
[TBL] [Abstract][Full Text] [Related]
24. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
25. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
26. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
Liu Y; Hall IJ; Filson C; Howard DH
Urol Oncol; 2021 Jul; 39(7):432.e1-432.e10. PubMed ID: 33308973
[TBL] [Abstract][Full Text] [Related]
27. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
28. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
29. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
30. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
31. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
32. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
Keegan KA; Dall'Era MA; Durbin-Johnson B; Evans CP
Cancer; 2012 Jul; 118(14):3512-8. PubMed ID: 22180322
[TBL] [Abstract][Full Text] [Related]
33. What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?
Mervin MC; Lowe A; Gardiner RA; Smith DP; Aitken J; Chambers SK; Gordon LG
Asia Pac J Clin Oncol; 2017 Jun; 13(3):152-159. PubMed ID: 28303657
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
35. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
36. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
37. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.
Al Hussein Al Awamlh B; Ballman KV; Ma X; Hu JC; Shoag JE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):714-717. PubMed ID: 32661433
[TBL] [Abstract][Full Text] [Related]
38. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy.
Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
[TBL] [Abstract][Full Text] [Related]
39. National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.
Weiner AB; Conti RM; Eggener SE
J Urol; 2016 May; 195(5):1383-1389. PubMed ID: 26707507
[TBL] [Abstract][Full Text] [Related]
40. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
